WuXi group wrestles with uncertainty over pharma tariffs
Drugs services giant WuXi AppTec cashed in a stake in Wuxi XDC to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another…
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
A family of biotech contracting companies in Wuxi has begun selling offshore assets under pressure from Western governments worried about national security. And a family feud in Shanghai has left a $1 billion luxury villa complex in limbo.
WuXi Biologics sells vaccine plant as new U.S. law looms
The Chinese drug services giant built an Irish factory to produce vaccines for Merck, but has now opted to sell the plant to the U.S.-based multinational for $500 million Key…
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
Leading pharmaceutical research outsourcing company WuXi AppTec Co. Ltd. (2359.HK; 603259.SH), announced on Tuesday that it has agreed to transfer its entire equity stakes in Advanced Therapies and Oxford Genetics…
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
Market talk is swirling that WuXi AppTec may be preparing to shed its cell and gene therapy business to limit potential exposure to U.S. biosecurity legislation Key Takeaways: The drug…
Kindstar Globalgene finds bargain in solid tumor testing acquisition
The testing services provider’s proposed $31.3 million purchase price for AnchorDx represents a heavy discount to the company’s earlier valuations Key Takeaways: Kindstar Globalgene’s proposed acquisition of AnchorDx would allow…
WuXi AppTec posts lower profits but avoids more share price pain
The pharmaceutical services giant delivered lackluster half-year earnings, with revenues and profits both falling, but investors were relieved that its U.S. business took only a minor hit Key Takeaways: U.S.…
Recent Articles
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
2269.HK
2359.HK
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK
603259.SHG
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK
603259.SHG
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK
603259.SHG
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK 603259.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Youdao looks to parent, global markets to revive stalling growth
DAO.US
-
Yalla revenue growth returns to double-digits ahead of new gaming push
YALA.US
